Cost of Revenue Comparison: Biogen Inc. vs Grifols, S.A.

Biogen vs. Grifols: A Decade of Cost Dynamics

__timestamp	Biogen Inc.	Grifols, S.A.
Wednesday, January 1, 2014	1171036000	1656170000
Thursday, January 1, 2015	1240400000	2003565000
Friday, January 1, 2016	1478700000	2137539000
Sunday, January 1, 2017	1630000000	2166062000
Monday, January 1, 2018	1816300000	2437164000
Tuesday, January 1, 2019	1955400000	2757459000
Wednesday, January 1, 2020	1805200000	3084873000
Friday, January 1, 2021	2109700000	2970522000
Saturday, January 1, 2022	2278300000	3832437000
Sunday, January 1, 2023	2533400000	4269276000
Monday, January 1, 2024	0

Unleashing insights

Cost of Revenue: A Tale of Two Giants

In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. Biogen Inc. and Grifols, S.A., two titans in the field, have shown distinct trends in their cost of revenue from 2014 to 2023. Over this period, Grifols, S.A. consistently outpaced Biogen Inc., with an average cost of revenue approximately 52% higher. Notably, Grifols' cost of revenue surged by 158% from 2014 to 2023, peaking at over $4.3 billion in 2023. In contrast, Biogen's cost of revenue grew by 116% during the same period, reaching $2.5 billion in 2023. This disparity highlights Grifols' expansive operational scale and possibly more extensive product offerings. As the industry evolves, these figures underscore the importance of strategic cost management in maintaining competitive advantage.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025